Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Acquired Localized Cutis Laxa due to Increased Elastin Turnover

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Omalizumab for chronic urticaria: a case series and overview of the literature

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

  2. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

  3. Cutaneous adverse reactions to anti-PD-1 treatment - a systematic review

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Alopecia areata (AA) is the most common immune-mediated hair loss disorder with a life-time prevalence of 2%. The pathogenesis of AA is not completely understood, but interferon gamma (INF-γ) and Janus kinases (JAK) may play a key role. Here, we present a case involving a male patient with psoriasis and psoriatic arthritis, who exhibited a rapid hair loss, diagnosed as AA, during ciclosporin treatment. As ciclosporin was unable to control his psoriasis, the treatment was changed to methotrexate injections, but the hair loss progressed into alopecia universalis. During treatment with the oral JAK inhibitor tofacitinib, the patient presented an almost complete hair remission on the scalp and partly on the eyebrows, eyelashes, beard, and chest. Furthermore, the patient experienced no joint complaints and his psoriasis was improved. Based on these findings, JAK inhibitors may be an optional treatment in complicated cases involving both rheumatological and dermatological diseases.

Original languageEnglish
JournalCase Reports in Dermatology
Volume12
Issue number2
Pages (from-to)150-154
Number of pages5
ISSN1662-6567
DOIs
Publication statusPublished - 2 Oct 2020

ID: 60995119